Reduction of GAS5 and FOXD3-AS1 long non-coding RNAs in patients with bipolar disorder.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
24 08 2023
24 08 2023
Historique:
received:
13
07
2023
accepted:
22
08
2023
medline:
28
8
2023
pubmed:
25
8
2023
entrez:
24
8
2023
Statut:
epublish
Résumé
Bipolar disorder (BD) patients suffer from severe disability and premature death because of failure in prognosis, diagnosis, and treatment. Although neural mechanisms of bipolar have not been fully discovered, studies have shown long noncoding RNAs (lncRNAs) can play an important role in signaling pathways such as PI3K/AKT pathway. There has been little study on deregulated lncRNAs and the lncRNAs' mode of action in the BD. Hence, we aimed to investigate the expression of PI3K/AKT pathway-related lncRNAs named TUG1, GAS5, and FOXD3-AS1 lncRNAs in the PMBC in 50 bipolar patients and 50 healthy controls. Our results showed that FOXD3-AS1 and GAS5 under-expressed significantly in bipolar patients compared to healthy controls (P = 0.0028 and P < 0.0001 respectively). Moreover, after adjustment, all P values remained significant (q value < 0.0001). According to the ROC curve, AUC (area under the curve), specificity, and sensitivity of these lncRNAs, GAS5 and FOXD3-AS1 might work as BD candidate diagnostic biomarkers. Taken together, the current results highlight that the dysregulation of FOXD3-AS1 and GAS5 may be associated with an increased risk of BD.
Identifiants
pubmed: 37620425
doi: 10.1038/s41598-023-41135-z
pii: 10.1038/s41598-023-41135-z
pmc: PMC10449891
doi:
Substances chimiques
Forkhead Transcription Factors
0
FOXD3 protein, human
0
Phosphatidylinositol 3-Kinases
EC 2.7.1.-
Proto-Oncogene Proteins c-akt
EC 2.7.11.1
RNA, Long Noncoding
0
GAS5 long non-coding RNA, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
13870Informations de copyright
© 2023. Springer Nature Limited.
Références
Arch Gen Psychiatry. 2011 Apr;68(4):340-50
pubmed: 21135314
Hum Gene Ther. 2020 Dec;31(23-24):1274-1287
pubmed: 32808542
Neuromolecular Med. 2021 Jun;23(2):327-334
pubmed: 33085068
Int J Mol Sci. 2021 May 13;22(10):
pubmed: 34068138
Medicina (Kaunas). 2019 Jul 24;55(8):
pubmed: 31344941
J Am Assoc Nurse Pract. 2015 Sep;27(9):530-42
pubmed: 26172568
Adv Exp Med Biol. 2017;1008:253-282
pubmed: 28815543
Am J Psychiatry. 2001 Mar;158(3):420-6
pubmed: 11229983
Gene. 2021 Sep 5;796-797:145803
pubmed: 34175394
Biomed Pharmacother. 2020 Dec;132:110778
pubmed: 33068927
Cell Biosci. 2020 May 29;10:74
pubmed: 32514332
Kaohsiung J Med Sci. 2019 Sep;35(9):527-534
pubmed: 31373759
Sci Rep. 2022 May 6;12(1):7479
pubmed: 35523833
Biol Res. 2020 Nov 19;53(1):53
pubmed: 33213523
Behav Sci (Basel). 2016 Jul 15;6(3):
pubmed: 27429010
Oncol Lett. 2019 Nov;18(5):4393-4402
pubmed: 31611948
Technol Cancer Res Treat. 2021 Jan-Dec;20:1533033821990074
pubmed: 33641529
Front Oncol. 2022 Feb 25;12:848296
pubmed: 35280790
Neuroscience. 2020 Jun 15;437:87-97
pubmed: 31982471
Neuron. 2021 May 5;109(9):1479-1496.e6
pubmed: 33765445
J Cell Mol Med. 2020 Jan;24(1):250-259
pubmed: 31709761
Mol Ther. 2018 Mar 7;26(3):755-773
pubmed: 29398485
Exp Mol Med. 2018 Apr 9;50(4):1-11
pubmed: 29628501
Biomed Pharmacother. 2021 May;137:111279
pubmed: 33493969
Epigenetics. 2023 Dec;18(1):2195305
pubmed: 36994860
Diseases. 2019 Feb 13;7(1):
pubmed: 30781836
J Neurooncol. 2019 Jul;143(3):525-536
pubmed: 31172354
Cancer Sci. 2018 Oct;109(10):3093-3104
pubmed: 30099814
PLoS One. 2021 Nov 3;16(11):e0252848
pubmed: 34731163
Am J Transl Res. 2016 Oct 15;8(10):4106-4119
pubmed: 27829996
Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7519-7525
pubmed: 31539141
Cell Biochem Funct. 2019 Jun;37(4):239-244
pubmed: 31017311
Acta Biochim Biophys Sin (Shanghai). 2021 Nov 10;53(11):1484-1494
pubmed: 34605863
J Stroke Cerebrovasc Dis. 2021 Mar;30(3):105550
pubmed: 33341564
Bioengineered. 2021 Dec;12(1):5266-5278
pubmed: 34424807